StockData
Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc (JAZZ) stock

JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30119% above fair value
$230.26−6.19 (-2.62%)

Close on Nov 20, 2026Market cap $14.95BP/E 75.0Yield –

Jazz Pharmaceuticals gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Jazz Pharmaceuticals's gross profit for the twelve months ending Dec 31, 2020 was $2.20B, up 9.5% year over year.

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2020Dec 31, 2020$611.15M+12.9%
Q3 FY2020Sep 30, 2020$554.85M+10.8%
Q2 FY2020Jun 30, 2020$530.20M+6.9%
Q1 FY2020Mar 31, 2020$501.55M+6.8%
Q4 FY2019Dec 31, 2019$541.18M+22.7%
Q3 FY2019Sep 30, 2019$500.92M+14.2%
Q2 FY2019Jun 30, 2019$495.75M+7.4%
Q1 FY2019Mar 31, 2019$469.83M+15.5%
Q4 FY2018Dec 31, 2018$441.00M+8.9%
Q3 FY2018Sep 30, 2018$438.62M+16.4%
Q2 FY2018Jun 30, 2018$461.38M+27.8%
Q1 FY2018Mar 31, 2018$406.93M+16.7%
Q4 FY2017Dec 31, 2017$404.85M+12.8%
Q3 FY2017Sep 30, 2017$376.77M–
Q2 FY2017Jun 30, 2017$360.98M–
Q1 FY2017Mar 31, 2017$348.61M–
Q4 FY2016Dec 31, 2016$358.96M–

More Jazz Pharmaceuticals figures

See a number that looks wrong?